Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.5 USD | -1.66% | +0.21% | -33.05% |
05-14 | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
05-10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.05% | 2.81B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.17% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Transcript : Amicus Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021